These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
675 related articles for article (PubMed ID: 17158544)
1. Role of cytokine therapy in 2006 and beyond for metastatic renal cell cancer. Parton M; Gore M; Eisen T J Clin Oncol; 2006 Dec; 24(35):5584-92. PubMed ID: 17158544 [TBL] [Abstract][Full Text] [Related]
3. [Cytokine therapy for metastatic renal cell carcinoma]. Eto M; Naito S Gan To Kagaku Ryoho; 2002 Oct; 29(10):1738-44. PubMed ID: 12402423 [TBL] [Abstract][Full Text] [Related]
10. Combination biologic therapy with interleukin-2 and interferon-alfa in the outpatient treatment of metastatic renal cell carcinoma. Figlin RA; Pierce WC; Belldegrun A Semin Oncol; 1993 Dec; 20(6 Suppl 9):11-5. PubMed ID: 8284686 [No Abstract] [Full Text] [Related]
11. Cytokine combinations: therapeutic use in patients with advanced renal cell carcinoma. Bukowski RM Semin Oncol; 2000 Apr; 27(2):204-12. PubMed ID: 10768599 [TBL] [Abstract][Full Text] [Related]
12. Tumor infiltrating dendritic cells predict treatment response to immmunotherapy in patients with metastatic renal cell carcinoma. Kobayashi M; Suzuki K; Yashi M; Yuzawa M; Takayashiki N; Morita T Anticancer Res; 2007; 27(2):1137-41. PubMed ID: 17465253 [TBL] [Abstract][Full Text] [Related]
13. Interleukin-2 based immunotherapy in patients with metastatic renal cell carcinoma. Donskov F Dan Med Bull; 2007 Nov; 54(4):249-65. PubMed ID: 18208677 [TBL] [Abstract][Full Text] [Related]
14. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma. Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M Urol Oncol; 2009; 27(6):598-603. PubMed ID: 18818106 [TBL] [Abstract][Full Text] [Related]
15. Leukocyte orchestration in blood and tumour tissue following interleukin-2 based immunotherapy in metastatic renal cell carcinoma. Donskov F; Bennedsgaard KM; Hokland M; Marcussen N; Fisker R; Madsen HH; Fode K; von der Maase H Cancer Immunol Immunother; 2004 Aug; 53(8):729-39. PubMed ID: 15088127 [TBL] [Abstract][Full Text] [Related]
16. New therapeutic developments in renal cell cancer. Prenen H; Gil T; Awada A Crit Rev Oncol Hematol; 2009 Jan; 69(1):56-63. PubMed ID: 18752971 [TBL] [Abstract][Full Text] [Related]
17. Update on the role of interleukin 2 and other cytokines in the treatment of patients with stage IV renal carcinoma. Atkins MB; Regan M; McDermott D Clin Cancer Res; 2004 Sep; 10(18 Pt 2):6342S-6S. PubMed ID: 15448028 [TBL] [Abstract][Full Text] [Related]
19. Immunotherapy for renal cell cancer in the era of targeted therapy. Coppin C Expert Rev Anticancer Ther; 2008 Jun; 8(6):907-19. PubMed ID: 18533800 [TBL] [Abstract][Full Text] [Related]